Weight Gain in Adults with Avoidant/Restrictive Food Intake Disorder Compared to Restrictive Anorexia Nervosa-Pilot Findings from a Longitudinal Study.

BACKGROUND: Avoidant/Restrictive Food Intake Disorder (ARFID) is characterized by persistent failure to meet nutritional needs, absence of body image distortion and often low body weight. Weight restorative treatment in ARFID-adults is provided for as in Anorexia Nervosa (AN), while the effect is unknown. The aim was to compare weight gain between ARFID and restrictive subtype of AN (AN-R), including exploring impact of medical factors and psychopathology. METHODS: Individuals with ARFID (n = 7; all cases enrolled over 5 years) and AN-R (n = 80) were recruited from the Prospective Longitudinal All-comers inclusion study in Eating Disorders (PROLED) during 5 years. All underwent weight restorative inpatient treatment. Clinical characteristics at baseline and weekly weight gain were recorded and compared. RESULTS: There were no significant differences at baseline weight, nor in weight gain between groups. Anxiety was statistically significantly higher in AN-R at baseline. CONCLUSIONS: Although there were differences in several clinical measures at baseline (Autism Quotient, symptom checklist, mood scores and Morgan Russel Outcome Scale), only anxiety was higher in AN-R. No differences in weight gain were observed, although mean values indicate a faster weight gain in the ARFID group. Standard weight restorative treatment in this study in adults with ARFID has similar weight gaining effect as in AN-R.

Methane loss from commercially operating biogas upgrading plants.

Biogas technology is one of the widely applied anaerobic digestion approaches to harvest methane from different wastes. Recently, methane loss from biogas plants and its environmental and economic consequences have been underlined, but not thoroughly researched. In this investigation, process related CH4 loss from nine different commercially operating biogas upgrading plants such as water scrubber, amine, and membrane-based plants was examined. The result of the measurements showed an average of 0.81% methane loss with respect to supplied methane to the upgrading plants. A methane loss up to 1.97% was detected in water scrubber methane upgrading technology and up to 0.56% loss from membrane technology, while 0.04% methane loss was detected in amine based upgrading, thus the water scrubber has shown the most detrimental effect as regards methane loss. The regenerative thermal oxidizer was further applied to reduce CH4 emission by 99.5% of the amount of CH4 in the waste gas from the upgrading unit, which ensures the sustainable process of biogas production.

An overview of microbial biogas enrichment.

Biogas upgrading technologies have received widespread attention recently and are researched extensively. Microbial biogas upgrading (biomethanation) relies on the microbial performance in enriched H2 and CO2 environments. In this review, recent developments and applications of CH4 enrichment in microbial methanation processes are systematically reviewed. During biological methanation, either H2 can be injected directly inside the anaerobic digester to enrich CH4 by a consortium of mixed microbial species or H2 can be injected into a separate bioreactor, where CO2 contained in biogas is coupled with H2 and converted to CH4, or a combination hereof. The available microbial technologies based on hydrogen-mediated CH4 enrichment, in particular ex-situ, in-situ and bioelectrochemical, are compared and discussed. Moreover, gas-liquid mass transfer limitations, and dynamics of bacteria-archaea interactions shift after H2 injection are thoroughly discussed. Finally, the summary of existing demonstration, pilot plants and commercial CH4 enrichment plants based on microbial biomethanation are critically reviewed.

The P2X7 receptor: a key player in immune-mediated bone loss?

Inflammatory diseases are often multiorganic diseases with manifestations not related directly to the primary affected organ. They are often complicated by a generalized bone loss that subsequently leads to osteoporosis and bone fractures. The exact mechanism for the accompanying bone loss is not understood in full detail, but factors such as glucocorticoid treatment, immobilization, malnutrition, and insufficient intake of vitamin D play a role. However, it has become evident that the inflammatory process itself is involved and the resulting bone loss is termed immune-mediated bone loss. It stems from an increase in bone resorption and the pro-inflammatory cytokines tumor necrosis factor alpha and interleukin 1 beta and has been shown to not only mediate the inflammatory response but also to strongly stimulate bone degradation. The purinergic P2X7 receptor is central in the processing of these two cytokines and in the initiation of the inflammatory response, and it is a key molecule in the regulation of both bone formation and bone resorption. The aim of this review is therefore to provide evidence-based novel hypotheses of the role of ATP-mediated purinergic signalling via the P2X7 receptor in immune-mediated bone loss and -osteoporosis.

Paget's disease of the bone after treatment with Denosumab: a case report.

Bone affection in Paget's disease is characterized by increased bone turnover localised at one or more sites of the skeleton. Bisphosphonates are the drugs of choice when treating the increased bone turnover in Paget's disease. However, in cases of decreased kidney function only less effective treatments that are available as bisphosphonates are contraindicated in these patients. We present a case of a male patient aged 86 years with GFR of 11 mL/min and Paget's disease successfully treated by Denosumab. The bone turnover and pain decreased upon treatment.

Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures.

The purinergic P2X7 receptor has a major role in the regulation of osteoblast and osteoclast activity and changes in receptor function may therefore affect bone mass in vivo. The aim of this study was to determine the association of non-synonymous single-nucleotide polymorphisms in the P2RX7 gene to bone mass and fracture incidence in post-menopausal women. A total of 1694 women (aged 45-58) participating in the Danish Osteoporosis Prevention Study were genotyped for 12 functional P2X7 receptor variants. Bone mineral density was determined at baseline and after 10 years. In addition, vertebral fracture incidence was documented at 10 years. We found that the rate of bone loss was clearly associated with the Arg307Gln amino acid substitution such that individuals heterozygous for this polymorphism had a 40% increased rate of bone loss. Furthermore, individuals carrying the Ile568Asn variant allele had increased bone loss. In contrast, the Gln460Arg polymorphism was associated with protection against bone loss. The Ala348Thr polymorphism was associated with a lower vertebral fracture incidence 10 years after menopause. Finally, we developed a risk model, which integrated P2RX7 genotypes. Using this model, we found a clear association between the low-risk (high-P2X7 function) alleles and low rate of bone loss. Conversely, high-risk (reduced P2X7 function) alleles were associated with a high rate of bone loss. In conclusion, an association was demonstrated between variants that reduce P2X7 receptor function and increased rate of bone loss. These data support that the P2X7 receptor is important in regulation of bone mass.